CMX157: Phase I/IIa ongoing

A DSMB recommended continuation of the open-label, dose-escalation Phase IIa portion of a Thai Phase I/IIa trial comparing 5, 10, 25, 50 and 100 mg oral CMX157 once daily for 4 weeks vs. 300 mg oral V...